Developer docs
API playgroundTry for free, no card

Search company profiles

Cogent Biosciences

Full company profile

uuid0002ffh

Namestring
Cogent Biosciences
Legal namestring
Cogent Biosciences, Inc.
Websiteurl
cogentbio.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Cogent Biosciences is a clinical-stage biotechnology company developing precision small-molecule kinase inhibitors for genetically defined diseases, with a primary focus on KIT-driven cancers and hematologic disorders. Founded in 2014/2015 and headquartered in Waltham, Massachusetts with a discovery facility in Boulder, Colorado, the company is publicly traded on NASDAQ (COGT). Its lead asset bezuclastinib (CGT9486) is a highly selective KIT inhibitor designed against the KIT D816V mutation, with positive pivotal data across three indications: NonAdvanced Systemic Mastocytosis (SUMMIT), Advanced Systemic Mastocytosis (APEX), and second-line GIST in combination with sunitinib (PEAK). Two NDAs have been accepted with PDUFA dates in November and December 2026, and a third NDA for AdvSM is planned for mid-2026.

The broader pipeline includes CGT1145, a JAK2 V617F mutant-selective inhibitor (>100x selectivity over wild-type JAK2) for myelofibrosis and related myeloproliferative neoplasms, plus preclinical-stage programs targeting KRAS(ON/OFF), wild-type-sparing PI3Kα, and ErbB2/HER2. Cogent is pre-revenue with no product sales and operates a pre-commercial model relying on future pharmaceutical product sales following FDA approval. Revenue mechanics will flow through traditional specialty pharmacy and oncology distribution channels to oncology and hematology HCPs, with projected bezuclastinib revenues of $170.5M in FY27 scaling to $678.6M by FY30 per Raymond James estimates. The go-to-market strategy is enterprise field sales targeting specialty centers treating rare disease patients.

Cogent has raised over $1.5 billion since inception across equity offerings, PIPEs, and non-dilutive debt, ending 2025 with $900.8M in cash and marketable securities (runway into 2028). The November 2025 concurrent offerings of common stock and $200M convertible notes due 2031 represent the largest single capital raise to date. Market capitalization reached approximately $5.29B in early 2026, reflecting strong investor validation of the bezuclastinib opportunity and pipeline breadth.

Short descriptiontext

Cogent Biosciences is a clinical-stage biotechnology company developing precision small-molecule kinase inhibitors, led by bezuclastinib for KIT-driven systemic mastocytosis and GIST. Pre-revenue, it is building a commercial organization for a planned H2 2026 launch targeting oncology and hematology specialists.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology therapeutics, kinase inhibitor development, biopharmaceutical drug discovery, small molecule cancer therapy, targeted rare disease treatment
Industry3 codes
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Precision Oncology Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical product sales
TypeOne Time License
Description

Pre-commercial biotech company expecting to generate revenue from commercialization of bezuclastinib and other drug candidates following FDA approval. Projected revenues of $170.5 million in FY27 growing to $678.6 million by FY30.

finance.yahoo.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cogent Biosciences is a clinical-stage biotechnology company developing precision small molecule therapeutics that target the underlying genetic drivers of cancer and rare diseases. Its lead asset, bezuclastinib (CGT9486), is a selective KIT inhibitor being advanced through pivotal trials for NonAdvanced Systemic Mastocytosis (NonAdvSM), Advanced Systemic Mastocytosis (AdvSM), and Gastrointestinal Stromal Tumors (GIST), with three NDA submissions planned and a commercial launch targeted for H2 2026. Earlier-stage pipeline assets include a JAK2 V617F inhibitor (CGT1145), an ErbB2/HER2 inhibitor, a wild-type-sparing PI3Kα inhibitor, and a pan-KRAS inhibitor.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 56% relative improvement in Total Symptom Score with -32.0 point mean reduction
+6 more records
Product and service3 records
1Bezuclastinib (CGT9486)
CategoryPrecision Oncology Therapeutics
Description

Investigational highly selective and potent oral KIT inhibitor targeting the KIT D816V mutation; being developed for NonAdvanced Systemic Mastocytosis, Advanced Systemic Mastocytosis, and second-line GIST (in combination with sunitinib). Designed for patients with KIT-driven hematologic and oncologic diseases.

2CGT1145 (JAK2 V617F Inhibitor)
CategoryPrecision Oncology Therapeutics
Description

Investigational potential best-in-class JAK2 V617F mutant-selective inhibitor (>100x selective over JAK2 WT) in preclinical development for myelofibrosis, polycythemia vera and essential thrombocythemia.

3Pan-KRAS Inhibitor
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Patient advocacy partnership supporting GIST patients through the GIST Hope Mosaic photo mosaic project honoring those impacted by GIST, and collaboration on patient education resources.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Patient advocacy partnership creating the Systemic Mastocytosis Mosaic featuring stories of individuals impacted by SM and those who support them, with global community contributions.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Blueprint Medicines markets AYVAKIT (avapritinib), the leading approved KIT D816V inhibitor for advanced and non-advanced systemic mastocytosis, directly competing with Cogent's bezuclastinib in the same indication and prescriber base.

TypeDirect peer
Description

Deciphera developed Qinlock (ripretinib) for fourth-line GIST, making it a direct competitor to bezuclastinib in the GIST indication, particularly for imatinib-resistant patients that Cogent's PEAK trial addresses.

TypeDirect peer
Description

Kura Oncology is developing tipifarnib, a farnesyl transferase inhibitor for HRAS-mutant and other solid tumors, with similar precision oncology positioning and biomarker-driven development approach targeting genetically defined cancers.

TypeEmerging player
Description

Syndax is developing revumenid for chronic Graft-versus-Host Disease and menin inhibitors for AML, sharing Cogent's precision medicine approach with strong board overlap (Arlene Morris sits on both boards).

TypeBroad incumbent
Description

Incyte markets ruxolitinib (JAKAFI), the established JAK1/2 inhibitor used in myelofibrosis and polycythemia vera, making it a relevant competitor for Cogent's CGT1145 JAK2 V617F selective inhibitor pipeline program.

6Bristol-Myers Squibb
TypeBroad incumbent
Description

BMS markets PIVYA (pirtobrutinib) and has a broad oncology portfolio, plus historical GIST franchise (sprycel), making it a relevant broad incumbent for benchmarking in oncology market access and competitive dynamics.

TypeBroad incumbent
Description

Pfizer markets sunitinib (Sutent), the standard-of-care second-line GIST therapy used as comparator in Cogent's PEAK trial, and is the acquirer of Array BioPharma where multiple Cogent executives previously worked.

TypeBroad incumbent
Description

Novartis markets imatinib (Gleevec), the first-line GIST therapy and the patient population from which Cogent's bezuclastinib combination treatment in PEAK addresses.

TypeEmerging player
Description

Ajax Therapeutics is developing next-generation JAK2 inhibitors for myeloproliferative neoplasms, directly competing with Cogent's CGT1145 JAK2 V617F program in the same target indication.

TypeEmerging player
Description

Schrödinger uses computational physics-based platform to discover and develop precision medicines targeting genetically defined diseases, sharing Cogent's precision oncology philosophy but using a distinct drug discovery modality.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles28 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors30 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cogent Biosciences

Precision Oncology Therapeuticscogentbio.com

Cogent Biosciences is a clinical-stage biotechnology company developing precision small-molecule kinase inhibitors, led by bezuclastinib for KIT-driven systemic mastocytosis and GIST. Pre-revenue, it is building a commercial organization for a planned H2 2026 launch targeting oncology and hematology specialists.

What Cogent Biosciences does

Cogent Biosciences is a clinical-stage biotechnology company developing precision small-molecule kinase inhibitors for genetically defined diseases, with a primary focus on KIT-driven cancers and hematologic disorders. Founded in 2014/2015 and headquartered in Waltham, Massachusetts with a discovery facility in Boulder, Colorado, the company is publicly traded on NASDAQ (COGT). Its lead asset bezuclastinib (CGT9486) is a highly selective KIT inhibitor designed against the KIT D816V mutation, with positive pivotal data across three indications: NonAdvanced Systemic Mastocytosis (SUMMIT), Advanced Systemic Mastocytosis (APEX), and second-line GIST in combination with sunitinib (PEAK). Two NDAs have been accepted with PDUFA dates in November and December 2026, and a third NDA for AdvSM is planned for mid-2026.

The broader pipeline includes CGT1145, a JAK2 V617F mutant-selective inhibitor (>100x selectivity over wild-type JAK2) for myelofibrosis and related myeloproliferative neoplasms, plus preclinical-stage programs targeting KRAS(ON/OFF), wild-type-sparing PI3Kα, and ErbB2/HER2. Cogent is pre-revenue with no product sales and operates a pre-commercial model relying on future pharmaceutical product sales following FDA approval. Revenue mechanics will flow through traditional specialty pharmacy and oncology distribution channels to oncology and hematology HCPs, with projected bezuclastinib revenues of $170.5M in FY27 scaling to $678.6M by FY30 per Raymond James estimates. The go-to-market strategy is enterprise field sales targeting specialty centers treating rare disease patients.

Cogent has raised over $1.5 billion since inception across equity offerings, PIPEs, and non-dilutive debt, ending 2025 with $900.8M in cash and marketable securities (runway into 2028). The November 2025 concurrent offerings of common stock and $200M convertible notes due 2031 represent the largest single capital raise to date. Market capitalization reached approximately $5.29B in early 2026, reflecting strong investor validation of the bezuclastinib opportunity and pipeline breadth.

Cogent Biosciences firmographics

Firmographics
Name
Cogent Biosciences
Legal name
Cogent Biosciences, Inc.
Website
https://cogentbio.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
251–500 employees
Short description
Cogent Biosciences is a clinical-stage biotechnology company developing precision small-molecule kinase inhibitors, led by bezuclastinib for KIT-driven systemic mastocytosis and GIST. Pre-revenue, it is building a commercial organization for a planned H2 2026 launch targeting oncology and hematology specialists.
Ownership category
akta.pro rank

Cogent Biosciences industry classification

Industry
Product category
Precision Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

Keywords

  • Precision oncology therapeutics
  • Kinase inhibitor development
  • Biopharmaceutical drug discovery
  • Small molecule cancer therapy
  • Targeted rare disease treatment

Where Cogent Biosciences is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Cogent Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

  1. Pharmaceutical product sales: Pre-commercial biotech company expecting to generate revenue from commercialization of bezuclastinib and other drug candidates following FDA approval. Projected revenues of $170.5 million in FY27 growing to $678.6 million by FY30.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Cogent Biosciences product offering

Product offering

Core offering

Cogent Biosciences is a clinical-stage biotechnology company developing precision small molecule therapeutics that target the underlying genetic drivers of cancer and rare diseases. Its lead asset, bezuclastinib (CGT9486), is a selective KIT inhibitor being advanced through pivotal trials for NonAdvanced Systemic Mastocytosis (NonAdvSM), Advanced Systemic Mastocytosis (AdvSM), and Gastrointestinal Stromal Tumors (GIST), with three NDA submissions planned and a commercial launch targeted for H2 2026. Earlier-stage pipeline assets include a JAK2 V617F inhibitor (CGT1145), an ErbB2/HER2 inhibitor, a wild-type-sparing PI3Kα inhibitor, and a pan-KRAS inhibitor.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bezuclastinib (CGT9486) Investigational highly selective and potent oral KIT inhibitor targeting the KIT D816V mutation; being developed for NonAdvanced Systemic Mastocytosis, Advanced Systemic Mastocytosis, and second-line GIST (in combination with sunitinib). Designed for patients with KIT-driven hematologic and oncologic diseases.
  • CGT1145 (JAK2 V617F Inhibitor) Investigational potential best-in-class JAK2 V617F mutant-selective inhibitor (>100x selective over JAK2 WT) in preclinical development for myelofibrosis, polycythemia vera and essential thrombocythemia.
  • Pan-KRAS Inhibitor

Quantifiable outcome

  • 56% relative improvement in Total Symptom Score with -32.0 point mean reduction
  • +6 more outcomes

Companies that use Cogent Biosciences

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Cogent Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Cogent Biosciences partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • The Life Raft GroupcoreStrategic or Co-development PartnerPatient advocacy partnership supporting GIST patients through the GIST Hope Mosaic photo mosaic project honoring those impacted by GIST, and collaboration on patient education resources.
  • The Mast Cell Disease SocietycoreStrategic or Co-development PartnerPatient advocacy partnership creating the Systemic Mastocytosis Mosaic featuring stories of individuals impacted by SM and those who support them, with global community contributions.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Cogent Biosciences competitors and assessment

Company assessment

Direct peers

  • Blueprint Medicines: Blueprint Medicines markets AYVAKIT (avapritinib), the leading approved KIT D816V inhibitor for advanced and non-advanced systemic mastocytosis, directly competing with Cogent's bezuclastinib in the same indication and prescriber base.
  • Deciphera Pharmaceuticals: Deciphera developed Qinlock (ripretinib) for fourth-line GIST, making it a direct competitor to bezuclastinib in the GIST indication, particularly for imatinib-resistant patients that Cogent's PEAK trial addresses.
  • Kura Oncology: Kura Oncology is developing tipifarnib, a farnesyl transferase inhibitor for HRAS-mutant and other solid tumors, with similar precision oncology positioning and biomarker-driven development approach targeting genetically defined cancers.

Emerging players

  • Syndax Pharmaceuticals: Syndax is developing revumenid for chronic Graft-versus-Host Disease and menin inhibitors for AML, sharing Cogent's precision medicine approach with strong board overlap (Arlene Morris sits on both boards).
  • Ajax Therapeutics: Ajax Therapeutics is developing next-generation JAK2 inhibitors for myeloproliferative neoplasms, directly competing with Cogent's CGT1145 JAK2 V617F program in the same target indication.
  • Schrödinger: Schrödinger uses computational physics-based platform to discover and develop precision medicines targeting genetically defined diseases, sharing Cogent's precision oncology philosophy but using a distinct drug discovery modality.

Broad incumbents

  • Incyte: Incyte markets ruxolitinib (JAKAFI), the established JAK1/2 inhibitor used in myelofibrosis and polycythemia vera, making it a relevant competitor for Cogent's CGT1145 JAK2 V617F selective inhibitor pipeline program.
  • Bristol-Myers Squibb: BMS markets PIVYA (pirtobrutinib) and has a broad oncology portfolio, plus historical GIST franchise (sprycel), making it a relevant broad incumbent for benchmarking in oncology market access and competitive dynamics.
  • Pfizer: Pfizer markets sunitinib (Sutent), the standard-of-care second-line GIST therapy used as comparator in Cogent's PEAK trial, and is the acquirer of Array BioPharma where multiple Cogent executives previously worked.
  • Novartis: Novartis markets imatinib (Gleevec), the first-line GIST therapy and the patient population from which Cogent's bezuclastinib combination treatment in PEAK addresses.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Cogent Biosciences social profiles

Digital presence

Cogent Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cogent Biosciences leadership team

Management profile

Number of profiles

Profiles28 records

Cogent Biosciences funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors30 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cogent Biosciences M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cogent Biosciences

What does Cogent Biosciences do?

Cogent Biosciences is a clinical-stage biotechnology company developing precision small molecule therapeutics that target the underlying genetic drivers of cancer and rare diseases. Its lead asset, bezuclastinib (CGT9486), is a selective KIT inhibitor being advanced through pivotal trials for NonAdvanced Systemic Mastocytosis (NonAdvSM), Advanced Systemic Mastocytosis (AdvSM), and Gastrointestinal Stromal Tumors (GIST), with three NDA submissions planned and a commercial launch targeted for H2 2026. Earlier-stage pipeline assets include a JAK2 V617F inhibitor (CGT1145), an ErbB2/HER2 inhibitor, a wild-type-sparing PI3Kα inhibitor, and a pan-KRAS inhibitor.

Is Cogent Biosciences a public or private company?

Cogent Biosciences is a public company. It is classified as public and is currently operating.

When was Cogent Biosciences founded?

Cogent Biosciences was founded in 2015. It employs 251 to 500 people.

Where is Cogent Biosciences based?

Cogent Biosciences is headquartered in Waltham, United States, in the North America region.

How does Cogent Biosciences make money?

One revenue line is on record: pharmaceutical product sales.

Who are Cogent Biosciences's main competitors?

Direct peers on record are Blueprint Medicines, Deciphera Pharmaceuticals and Kura Oncology. Emerging players are Syndax Pharmaceuticals, Ajax Therapeutics and Schrödinger. Broad incumbents are Incyte, Bristol-Myers Squibb, Pfizer and Novartis.

Does Cogent Biosciences have an API?

No public API is recorded for Cogent Biosciences.

What industry is Cogent Biosciences in?

Cogent Biosciences's product category is Precision Oncology Therapeutics. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAIALAB, Lead Optimization & Preclinical Candidate Selection. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooCogent Biosciences (COGT) Stock Looks Fully Priced Against Its Asset BaseCogent Biosciences' stock trades at a price-to-book of about 10.7x, versus an industry average of 1.7x and a peer group average of 66.3x. The valuation is a clear premium to the sector but below the highest peer multiples, and the market's assignment of value beyond current net assets remains the key question.Investing.comCogent Biosciences at Jefferies: launch plans hinge on bezuclastinibCogent Biosciences outlined its bezuclastinib launch plans at Jefferies, awaiting three FDA decisions for GIST, non-advanced, and advanced systemic mastocytosis. The drug showed a hazard ratio of 0.50 in GIST, with no liver failures or Hy's Law cases. Management expects a commercial launch after approval, with a JAK2 inhibitor program on track for an IND filing.Seeking AlphaCogent Biosciences, Inc. (COGT) Presents at UBS Global Biopharma Conference 2026 TranscriptCogent Biosciences CEO Andrew Robbins discussed the company's drug pipeline at the UBS Global Biopharma Conference, stating the company is on the brink of 2-3 potential FDA approvals, with two potentially coming in the next couple of months. The lead asset, bezuclastinib, is a selective KIT mutant inhibitor under development for three distinct patient populations.Quiver QuantitativeCogent Biosciences Slides as Investors Digest Recent Results and Await Key FDA Decision | COGT Stock NewsCogent Biosciences stock fell 7.1% after a quarterly update showing a wider net loss and higher administrative spending ahead of a potential bezuclastinib launch. The decline may reflect risk-taking ahead of the November 30, 2026 FDA decision for bezuclastinib in GIST, with no new negative news cited.MarketBeatCogent Biosciences (COGT) Projected to Release Earnings on FridayCogent Biosciences is expected to report Q3 2026 earnings on Friday, with analysts projecting a loss of $0.5573 per share and revenue of $0.75 million. The stock opened at $31.96, and analyst ratings range from buy to sell, with a consensus price target of $51.56.American Banking and Market NewsCogent Biosciences (COGT) Projected to Post Quarterly Earnings on FridayCogent Biosciences is expected to report Q3 2026 earnings on Friday, with analysts projecting a loss of $0.5573 per share and revenue of $0.75 million. The stock opened at $31.96, and analysts have an average price target of $51.56, with ratings ranging from Strong Buy to Sell.Stock TitanCogent Biosciences to Speak at Guggenheim ConferenceCogent Biosciences announced its participation in a fireside chat at the Guggenheim Healthcare Innovation Conference in Boston on November 10, 2026. The company also granted inducement equity awards to six new employees, including options for 22,000 shares and 16,500 restricted stock units.Business & FinancialCogent Biosciences To Participate In The Guggenheim Healthcare Innovation ConferenceCogent Biosciences will participate in the Guggenheim Healthcare Innovation Conference, with a live webcast and replay available. The company's Compensation Committee approved inducement equity awards to six new employees, including 22,000 options and 16,500 RSUs. The awards vest over four years.MarketBeatCogent Biosciences, Inc. (COGT) - What Are Investment Firms Saying About This Stock?Analysts rate Cogent Biosciences a Moderate Buy with an average price target of $51.56. The company reported a quarterly loss of $0.52 per share, beating estimates, and has a market cap of $5.42 billion. Institutional investors have recently acquired new stakes in the stock.MarketBeatCogent Biosciences, Inc. $COGT Shares Sold by Assenagon Asset Management S.A.Assenagon Asset Management S.A. reduced its Cogent Biosciences stake by 18% in Q3, selling 259,226 shares and holding 1,182,530 shares worth $37.865 million. Analysts have an average "Moderate Buy" rating with a target price of $51.56, while the stock opened at $29.52.